Robert White - Medtronic PLC President
| MDT Stock | USD 79.48 0.29 0.37% |
President
Mr. Robert J. White is Executive Vice President and President of Medtronics Minimally Invasive Therapies Group of the company. He joined Medtronic upon the close of the Covidien acquisition by Medtronic in 2015 as President for the APAC Region, based in Singapore. In this role, White was responsible for the commercial growth of Medtronics business in the region, including leadership for Medtronics four main product and therapy groups, regional business development efforts, government and partner development strategies, talent development and retention, and the operations of the companys enabling functions. since 2021.
| Age | 61 |
| Tenure | 3 years |
| Address | 20 On Hatch, Dublin, Ireland, 2 |
| Phone | 353 1 438 1700 |
| Web | https://www.medtronic.com |
Robert White Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert White against Medtronic PLC stock is an integral part of due diligence when investing in Medtronic PLC. Robert White insider activity provides valuable insight into whether Medtronic PLC is net buyers or sellers over its current business cycle. Note, Medtronic PLC insiders must abide by specific rules, including filing SEC forms every time they buy or sell Medtronic PLC'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert White over a month ago Disposition of 10000 shares by Robert White of AtriCure at 15.96 subject to Rule 16b-3 | ||
Robert White over six months ago Disposition of 12397 shares by Robert White of Medtronic PLC subject to Rule 16b-3 | ||
Robert White over a year ago Exercise or conversion by Robert White of 20000 shares of AtriCure subject to Rule 16b-3 |
Medtronic PLC Management Efficiency
The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Samraat Raha | Agilent Technologies | 51 | |
| Aimee Hoyt | Illumina | 47 | |
| Michael Boxer | Thermo Fisher Scientific | 58 | |
| Mark Doak | Agilent Technologies | 63 | |
| Susan Hardy | Charles River Laboratories | N/A | |
| Sherry Buck | Waters | 55 | |
| Francis Kim | Waters | 51 | |
| Peter Hornstra | Thermo Fisher Scientific | 59 | |
| Stephen Williamson | Thermo Fisher Scientific | 57 | |
| Rohit Khanna | Waters | 58 | |
| William Barbo | Charles River Laboratories | 63 | |
| Nicholas Naclerio | Illumina | 53 | |
| Robert Carson | Waters | 46 | |
| David Terricciano | Waters | 61 | |
| AmirAli Talasaz | Guardant Health | 44 | |
| Charles Dadswell | Illumina | 65 | |
| Jacob Thaysen | Agilent Technologies | 49 | |
| Tristan Orpin | Illumina | 49 | |
| Garret Hampton | Illumina | 52 | |
| Davide Molho | Charles River Laboratories | 47 | |
| John Lynch | Waters | N/A | |
Management Performance
| Return On Equity | 0.0817 | ||||
| Return On Asset | 0.0423 |
Medtronic PLC Leadership Team
Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brett Wall, Executive Vice President and President Restorative Therapies Group | ||
| Jennifer Kirk, Chief Accounting Officer, Global Controller | ||
| Bradley Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Scott Donnelly, Lead Independent Director | ||
| Kenneth Washington, Senior Officer | ||
| Richard Anderson, Lead Independent Director | ||
| Ryan Weispfenning, Vice President - Investor Relations | ||
| Mark Ploof, Senior Services | ||
| Sean Lennon, Chief Officer | ||
| Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group | ||
| Elizabeth Nabel, Independent Director | ||
| Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer | ||
| James Lenehan, Independent Director | ||
| John Liddicoat, Executive Vice President and President Americas Region | ||
| Shirley Jackson, Independent Director | ||
| Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group | ||
| Preetha Reddy, Independent Director | ||
| Kevin Lofton, Independent Director | ||
| Craig Arnold, Independent Director | ||
| Robert Pozen, Independent Director | ||
| Kendall Powell, Lead Independent Director | ||
| Bryan Hanson, Executive VP and Group President of Minimally Invasive Therapies Group | ||
| Sally Saba, Chief Inclusion and Diversity Officer | ||
| Denise OLeary, Independent Director | ||
| Omar Ishrak, Chairman of the Board, Chief Executive Officer | ||
| Brad Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Ivan Fong, General VP | ||
| Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio | ||
| Gary Ellis, CFO and Executive VP | ||
| Carol Surface, Chief Human Resource Officer, Senior Vice President | ||
| Karen Parkhill, Chief Financial Officer, Executive Vice President | ||
| Geoff Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Michael Leavitt, Independent Director | ||
| Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Randall Hogan, Independent Director | ||
| Andrea Goldsmith, Independent Director | ||
| Robert Hoedt, Executive Vice President and President - EMEA Region | ||
| MSc MD, Medical Scientific | ||
| Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group |
Medtronic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0817 | ||||
| Return On Asset | 0.0423 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 122.22 B | ||||
| Shares Outstanding | 1.33 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 85.20 % | ||||
| Number Of Shares Shorted | 12.43 M | ||||
| Price To Earning | 20.44 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medtronic PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Medtronic Stock please use our How to Invest in Medtronic PLC guide.Note that the Medtronic PLC information on this page should be used as a complementary analysis to other Medtronic PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Medtronic Stock analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Medtronic PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medtronic PLC. If investors know Medtronic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medtronic PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.078 | Dividend Share 2.75 | Earnings Share 3.15 | Revenue Per Share 24.298 | Quarterly Revenue Growth 0.047 |
The market value of Medtronic PLC is measured differently than its book value, which is the value of Medtronic that is recorded on the company's balance sheet. Investors also form their own opinion of Medtronic PLC's value that differs from its market value or its book value, called intrinsic value, which is Medtronic PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medtronic PLC's market value can be influenced by many factors that don't directly affect Medtronic PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medtronic PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medtronic PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medtronic PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.